New TB vaccine trial launches: could this be the shot We've been waiting for?
NCT ID NCT06732583
First seen Jan 07, 2026 · Last updated Apr 28, 2026 · Updated 15 times
Summary
This early-stage study tests a new vaccine called Ad5-105K to see if it is safe and triggers an immune response against tuberculosis (TB). It involves 36 healthy adults aged 18 to 49 who have been exposed to TB but have not developed the disease. Participants receive either the vaccine or a placebo, and researchers monitor for side effects and measure antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rumah Sakit Islam Jakarta Cempaka Putih
RECRUITINGJakarta, Indonesia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.